-
Mashup Score: 2Neuvivo Expands Board of Directors in Preparation of Upcoming NDA Review with the Appointment of Robert Baffi, PhD, MBA - 19 day(s) ago
Neuvivo Expands Board of Directors in Preparation of Upcoming NDA Review with the Appointment of Robert Baffi, PhD, MBA Neuvivo, a pioneering company in biopharmaceutical innovation, is excited to announce the expansion of its Board of Directors with the appointment of Dr. Robert Baffi, PhD, MBA, a seasoned leader in the industry. This strategic addition underscores Neuvivo’s commitment to advancing its mission and driving growth. Dr. Baffi brings over 30 years of extensive experience in the biopharmaceuti
Source: www.morningstar.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 1Oracle Health to Apply for TEFCA QHIN Status - 20 day(s) ago
Pioneering the future of national healthcare interoperability, helping simplify patient information sharing between healthcare providers, and empowering patients to control their o wn data NASHVILLE, Tenn., Oct. 28, 2024 /PRNewswire/ — Oracle Health Summit – Oracle Health today announced that it intends to begin the process to become a Qualified Health Information Network (QHIN) as a part of the Trusted Exchange Framework and Common Agreement (TEFCA). Becoming a QHIN will allow Oracle Health to
Source: www.morningstar.comCategories: General Medicine News, General HCPsTweet-
Big news today (and great for TEFCA) - I suspect we will see a flurry of announcement from Oracle health this week from Nashville - Oracle Health to Apply for TEFCA QHIN Status https://t.co/qj8KV1vB6I
-
-
Mashup Score: 5LEO Pharma Launches Talk to the Hand Campaign to Raise Awareness of the Impact of Chronic Hand Eczema - 25 day(s) ago
Talk to the Hand aims to raise healthcare providers’ awareness of the physical symptoms and emotional impact of chronic hand eczema (CHE) — a debilitating skin condition for which there are currently no FDA-approved treatments. 1 CHE is a chronic, debilitating disease characterized by itch and pain, which negatively impacts patients’ quality of life, psychological well-being, daily lives, physical functioning and ability to work. 2,3 Talk to the Hand highlights the challenges of diagnosing CHE, including
Source: www.morningstar.comCategories: General Medicine News, Allergy-ImmunologyTweet-
#LEO Pharma Launches Talk to the Hand Campaign to Raise Awareness of the Impact of #Chronic #Hand #Eczema https://t.co/Y3Hw5SphuF https://t.co/KJJzwVBtJQ
-
-
Mashup Score: 0TytoCare and Frontier Health Partner to Provide Virtual-First Primary Care to Individuals and Employees across the United States - 1 month(s) ago
NEW YORK, Oct. 14, 2024 (GLOBE NEWSWIRE) — TytoCare is partnering with Frontier Health to offer a virtual extension of Frontier Health’s Direct Primary Care offering. Frontier Health is a Texas-based direct primary care organization with nine brick-and-mortar locations and 30,000+ contracted members across the United States. Through this collaboration, members of Frontier’s virtual care extensions will receive a TytoCare Home Smart Clinic device, at no additional cost, to visit their primary care
Source: www.morningstar.comCategories: General Medicine News, General HCPsTweet-
.@TytoCare and Frontier Health Partner to Provide Virtual-First #PrimaryCare to Individuals and Employees across the United States | #virtualcare https://t.co/iWequVbBfw
-
-
Mashup Score: 26Independent Directors of 23andMe Resign from Board - 2 month(s) ago
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2024 (GLOBE NEWSWIRE) — The independent directors of the Board of 23andMe Holding Co. (Nasdaq: ME), today sent the following letter to Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, in which the independent directors have provided their resignation from the Board, effective immediately: We, the independent directors of the 23andMe Board, hereby tender our resignations, effective immediately. After months of work,
Source: www.morningstar.comCategories: General Medicine News, General HCPsTweet-
Independent Directors of 23andMe Resign from Board https://t.co/1QVwCwbd1a
-
-
Mashup Score: 76EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) - 3 month(s) ago
European Commission decision follows FDA approval in the United States on August 9, 2024 SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) — ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to the development of products to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today that the European Commission has approved EUR neffy® (adrenaline nasal spray) for the emergency treatment of allergic reactions (anaphylaxis) on August 22,
Source: www.morningstar.comCategories: General Medicine News, Allergy-ImmunologyTweet-
#EURneffy (adrenaline nasal spray) approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (#anaphylaxis). https://t.co/CFv27ikG6b https://t.co/18qnFz8VTG
-
-
Mashup Score: 32
REDMOND, Wash., Aug. 21, 2024 (GLOBE NEWSWIRE) — Pattern Computer®, Inc. (“Pattern” or “the Company”) today announced that Pattern and the Medical College of Wisconsin (MCW) Cancer Center have launched a new pilot study to assess the detection of cancers through ProSpectral™ analysis of saliva, potentially ushering in a new era of cancer screening. This study will seek to assess biological markers for certain cancers through salivary diagnostics, a relatively new tool for early detection cancer screening.
Source: www.morningstar.comCategories: General Medicine News, Hem/OncsTweet-
Excited to help lead project. Detecting cancer via easy saliva test. Unique technology. Pattern and Medical College of Wisconsin Launch New Pilot Study to Assess Detection of Head, Neck and Lung Cancers Through ProSpectral™ Saliva Analysis | Morningstar https://t.co/ESv0RHtun8
-
-
Mashup Score: 1Balderton Announces $1.3B in New Funds to Back Europe’s Top Entrepreneurs as They Build World-Changing Businesses - 3 month(s) ago
Balderton Announces $1.3B in New Funds to Back Europe’s Top Entrepreneurs as They Build World-Changing Businesses Balderton Capital, one of Europe’s leading technology venture capital firms, today announced its $615 million Early Stage Fund IX and $685 million Growth Fund II, to back Europe’s most ambitious entrepreneurs from seed stage through IPO. “At Balderton, we believe the best way to change the world is to build a business – and that many of these world-changing businesses will be built in
Source: www.morningstar.comCategories: General Medicine News, Future of MedicineTweet-
Balderton’s investment history spans technology sectors including AI, fintech, B2B SaaS, #digitalhealth, mobility, gaming and marketplaces. https://t.co/V0M4u9tnj3
-
-
Mashup Score: 0
Singapore’s National Precision Medicine (NPM) programme will sequence 10,000 genomes to improve understanding of genetic architecture and diversity in Singapore’s multi-ethnic Asia population through advanced, nanopore-based sequencing technology Oxford Nanopore Technologies (Oxford Nanopore) has announced a landmark project with Singapore’s National Precision Medicine (NPM) programme, led by Precision Health Research, Singapore (PRECISE), aimed at developing a comprehensive structural variant catalogue
Source: www.morningstar.comCategories: General Medicine News, General HCPsTweet-
#Singapore’s National #PrecisionMedicine (NPM) Programme Engages Oxford @Nanopore to Advance Understanding of the #Genetics of Singapore’s Multi-Ethnic Population: will focus on sequencing 10,000 genomes including Malay, Indian, and Chinese communities https://t.co/knX64UGRyG
-
-
Mashup Score: 0Atlantic Health System and Mevion Announce Plans to Bring Newest Proton Therapy Technology to Cancer Patients - 5 month(s) ago
The MEVION S250-FIT Proton Therapy System will be installed at Morristown Medical Center’s Carol G. Simon Cancer Center Atlantic Health System, an integrated health care system setting standards for quality health care in New Jersey, Pennsylvania and the New York metropolitan area, and Mevion Medical Systems, the leading provider of compact single-room proton therapy systems, have announced Atlantic Health System’s plans to acquire and install a MEVION S250-FIT Proton Therapy System™* at the Carol G.
Source: www.morningstar.comCategories: General Medicine News, Hem/OncsTweet-
Now across the national news wires https://t.co/amQy0T83Zv https://t.co/cgpv3GZ3cm
-
I sure hope they've designed their next trial! https://t.co/tCKvTxm5WG